The two organizations will produce educational materials about the medicine and its importance for people living with type 1 and 2 diabetes.
American Diabetes Assoctiation
The American Diabetes Association (ADA) announced a multiyear strategic partnership with Xeris Pharmaceuticals. The two organizations will work together on a campaign to raise awareness about the importance of glucagon.
According to the ADA, nearly half of all people with type 1 diabetes suffer from at least one severe hypoglycemia event each year. For people with type 2 diabetes, that number is about 21%. Glucagon is an effective treatment to prevent this, although the ADA notes that it is still under prescribed. As part of its partnership with Xeris, the ADA will produce educational materials aimed about both health care professionals and patients.
In a press release, the ADA’s CEO Charles Henderson said, “Severe hypoglycemia is life-threatening, and people with diabetes on blood glucose-lowering medication are at risk for hypoglycemia. Thus, we must act with urgency to educate people about the importance of having a treatment plan in place that includes having glucagon on hand. Through this important partnership, we can save lives by ensuring individuals with diabetes who are treated with insulin have access to glucagon, preferably a ready-to-use formulation, so they can make a plan and be ready."
In the same press release, Xeris’ CEO John Shannon added, “Severe hypoglycemia is associated with up to a three-time increased risk of death in people with diabetes.4,5,6 Xeris is proud to collaborate with the ADA to urge adoption of their strengthened clinical practice recommendations around the treatment of severe hypoglycemia. The stakes are too high for so many patients at risk to be without a safety net. Our mutual commitment is to fight for all patients living with diabetes and ensure that they can face severe low blood glucose emergencies with confidence by always having a ready-to-use glucagon on hand."
The importance of Glucagon is noted in the ADA’s updated Standards of Care for 2025, which the organization announced in December, 2024.2 At the time, the ADA’s senior vice president of health care improvement Nuha El Sayed, MD, MMSc, noted, “"The latest ADA guidelines combine comprehensive, evidence-based recommendations for diabetes care with actionable guidance to enable health care professionals provide the best care possible for those living with diabetes.”
The ADA regularly partners with organizations for various educational campaigns related to the treatment of diabetes. In November 2024, the organization announced a partnership with Estes Express Lines. As a result, the freight carrier decorated its trailers with decals promoting the Drive Out Diabetes campaign.3
In a press release issued at the time, Estes president and COO Webb Estes said, “By leveraging our presence on roadways all over the country, we're able to raise awareness and reach more people about important causes, like diabetes. We look forward to seeing the impact of this new program and letting everyone know about the causes and nonprofits that Team Estes supports and believes in."
Chair of the ADA’s board of directors Rhodes Ritenour added, “American Diabetes Month is the perfect time to roll out this unique way of raising awareness about diabetes. We're grateful to Estes Express Lines for joining us in the fight to improve the lives of people affected by diabetes—and ultimately to find a cure."
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves AbbVie’s Rinvoq as First Oral JAK Inhibitor for Giant Cell Arteritis
April 30th 2025AbbVie secures FDA approval for Rinvoq as the first oral Janus kinase inhibitor indicated for giant cell arteritis, expanding its immunology portfolio and signaling strategic growth opportunities in underserved autoimmune markets.